Leslie Dakin
Pfizer (United States)(US)Vertex Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Renal Diseases and Glomerulopathies, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Immune Response and Inflammation, Immune Cell Function and Interaction, interferon and immune responses
Most-Cited Works
- → Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay(2017)159 cited
- → Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)(2016)111 cited
- → The catalytic mechanism of cyclic GMP‐AMP synthase (cGAS) and implications for innate immunity and inhibition(2017)67 cited
- → Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists(2016)60 cited
- → Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors(2016)36 cited
- → Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease(2025)17 cited
- → Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca2+ dependent allosteric binding site(2025)8 cited
- → Small Molecule APOL1 Inhibitors Block APOL1 Pore Function and Reduce Proteinuria in an APOL1-Mediated Kidney Disease Mouse Model(2021)3 cited
- → Small Molecule Inhibition of APOL1 Channel Activity Protects Podocytes from Mitochondrial Dysfunction, Cell Death, and Barrier Disruption Induced by APOL1 Risk Variants(2024)